Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Research Article

Polygenic Regulation by Flos Daturae in the Treatment of Breast Cancer: A Study based on Network Pharmacology and Bioinformatics

Author(s): Yang Xiao, Mengcong Ma, Yichen Li and Yunfeng Xiao*

Volume 20, Issue 6, 2023

Published on: 24 February, 2023

Page: [649 - 661] Pages: 13

DOI: 10.2174/1570180820666230214104234

Price: $65

Abstract

Background: In recent years, Chinese herbal medicine has been gradually emerging as a suitable treatment option for breast cancer. However, the mechanism underlying its effects remains to be elucidated.

Objective: The drug targets and Flos Daturae targets were intersected to obtain 86 component-disease intersection genes.

Methods: The String database and Cytoscape3.8.0 were employed, and finally, AKT1, MYC, EGFR, MAPK14 PTGS2, and VEGFA were obtained as the six core genes.

Results: According to the Gene Expression Profiling Interactive Analysis (GEPIA), six core gene correlation analysis figures were constructed. The GO enrichment analysis and the KEGG pathway enrichment analysis were conducted using the R package. Finally, molecular docking between the core genes and the main active components was performed for verification.

Conclusion: The results indicated that Flos Daturae has multiple components and multiple targets that regulate the body functions, through which it plays a role in the treatment of breast cancer. In addition, it was inferred that polygenic regulation is better than the single-gene approach in breast cancer treatment.

« Previous Next »
Graphical Abstract

[1]
Coughlin, S.S. Epidemiology of breast cancer in women. Adv. Exp. Med. Biol., 2019, 1152, 9-29.
[http://dx.doi.org/10.1007/978-3-030-20301-6_2] [PMID: 31456177]
[2]
Li, H.; Hu, B.; Guo, Z.; Jiang, X.; Su, X.; Zhang, X. Correlation of UGT2B7 polymorphism with cardiotoxicity in breast cancer patients undergoing epirubicin/cyclophosphamide-docetaxel adjuvant chemotherapy. Yonsei Med. J., 2019, 60(1), 30-37.
[http://dx.doi.org/10.3349/ymj.2019.60.1.30] [PMID: 30554488]
[3]
Jain, V.; Kumar, H.; Anod, H.V.; Chand, P.; Gupta, N.V.; Dey, S.; Kesharwani, S.S. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. J. Control. Release, 2020, 326, 628-647.
[http://dx.doi.org/10.1016/j.jconrel.2020.07.003] [PMID: 32653502]
[4]
Barzaman, K.; Karami, J.; Zarei, Z.; Hosseinzadeh, A.; Kazemi, M.H.; Moradi-Kalbolandi, S.; Safari, E.; Farahmand, L. Breast cancer: Biology, biomarkers, and treatments. Int. Immunopharmacol., 2020, 84, 106535.
[http://dx.doi.org/10.1016/j.intimp.2020.106535] [PMID: 32361569]
[5]
Thorat, M.A.; Balasubramanian, R. Breast cancer prevention in high-risk women. Best Pract. Res. Clin. Obstet. Gynaecol., 2020, 65, 18-31.
[http://dx.doi.org/10.1016/j.bpobgyn.2019.11.006] [PMID: 31862315]
[6]
Maughan, K.L.; Lutterbie, M.A.; Ham, P.S. Treatment of breast cancer. Am. Fam. Physician, 2010, 81(11), 1339-1346.
[PMID: 20521754]
[7]
Fahad Ullah, M. Breast cancer: Current perspectives on the disease status. Adv. Exp. Med. Biol., 2019, 1152, 51-64.
[http://dx.doi.org/10.1007/978-3-030-20301-6_4] [PMID: 31456179]
[8]
Nagini, S. Breast cancer: Current molecular therapeutic targets and new players. Anticancer. Agents Med. Chem., 2017, 17(2), 152-163.
[http://dx.doi.org/10.2174/1871520616666160502122724] [PMID: 27137076]
[9]
Lyons, T.G. Targeted therapies for triple-negative breast cancer. Curr. Treat. Options Oncol., 2019, 20(11), 82.
[http://dx.doi.org/10.1007/s11864-019-0682-x] [PMID: 31754897]
[10]
Vermillion, K.; Holguin, F.O.; Berhow, M.A.; Richins, R.D.; Redhouse, T.; O’Connell, M.A.; Posakony, J.; Mahajan, S.S.; Kelly, S.M.; Simon, J.A.; Dinoxin, B a withanolide from Datura inoxia leaves with specific cytotoxic activities. J. Nat. Prod., 2011, 74(2), 267-271.
[http://dx.doi.org/10.1021/np1004714] [PMID: 21280589]
[11]
Liu, Y.; Pan, J.; Sun, Y.P.; Wang, X.; Liu, Y.; Yang, B.Y.; Kuang, H.X. Immunosuppressive withanolides from the flower of Datura metel L. Fitoterapia, 2020, 141104468
[http://dx.doi.org/10.1016/j.fitote.2019.104468] [PMID: 31887326]
[12]
Liu, Y.; wang, X.; Yang, BY; Xia, YG; Wang, Q; Hong, Kuang HX Study on the chemical constituents of daffodil seeds. Acta. Chinese Med. Pharmacol., 2021, 43(08), 2092-2100.
[13]
Zhu, JL; Deng, YJ; He, Y. Research progress on chemical constituents, pharmacological action and clinical application of Flos officinalis. Chinese J. Experimental Formulae, 2021, (24), 201-209.
[14]
Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y.; Xu, X.; Li, Y.; Wang, Y.; Yang, L. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform., 2014, 6(1), 13.
[http://dx.doi.org/10.1186/1758-2946-6-13] [PMID: 24735618]
[15]
Wang, Z.; Shi, Z.F.; Wang, F.Y.; Li, W.D.; Han, L Mechanism of Hanshi Bi granules in the treatment of ankylosing spondylitis based on network pharmacology. Chinese J. Tissue Eng. Res., 2020, 11(24), 1738-1744.
[16]
Wishart, D.S. DrugBank and its relevance to pharmacogenomics. Pharmacogenomics, 2008, 9(8), 1155-1162.
[http://dx.doi.org/10.2217/14622416.9.8.1155] [PMID: 18681788]
[17]
Fishilevich, S.; Nudel, R.; Rappaport, N.T. Gene hancer: Genome-wide integration of enhancers and target genes in gene cards. Database (Oxford), 2017, 2017
[18]
Luo, P.; Tian, L.P.; Ruan, J.; Wu, F.X. Disease gene prediction by integrating ppi networks, clinical RNA-seq data and omim data. IEEE/ACM Trans. Comput. Biol. Bioinformatics, 2019, 16(1), 222-232.
[http://dx.doi.org/10.1109/TCBB.2017.2770120] [PMID: 29990218]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy